Critical Biologics Corporation
Cambridge
About Critical Biologics Corporation
Critical Biologics Corp., a development stage biotechnology company, develops and commercializes diagnostics and therapeutics that predict and regulate inflammatory responses to life-threatening diseases. The company focuses on a theranostic approach to treat critical care patients with low plasma gelsolin (pGSN) levels at high risk of life-threatening complications. Its products include SolinDx, an ELISA assay kit used for the measurement of pGSN in human plasma samples; ActinDx, an ELISA assay kit used for the quantitative measurement of the amount of circulating actin in serum; and Solinex, an investigational drug. The company has a strategic partnership wit QSV Biologics, Ltd. to manufacture pharmaceutical recombinant human pGSN. Critical Biologics Corp. was founded in 2004 and is based in Cambridge, Massachusetts with an additional office in Hunterdon County, New Jersey.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $500.0K
- Last round: Debt Financing (Jul 2009)
- Website: criticalbiologics.com
- Phone: 908-439-9768
Industries & Categories
Biotechnology, Health Diagnostics, Manufacturing, Medical
Canonical: https://fsome.com/organization/critical-biologics-corporation-2200233 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.